Meta AnalysisID 2769
石杉碱甲对痴呆和轻度认知障碍的效果：系统评价的概述
CRD42020168194
What is the efficacy and effectiveness of Huperzine A in the treatment of dementia and mild cognitive impairment?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2769
- Evidence Id
- 11327
- Core Evidence Id
- 11327
- Source Meta Analysis Id
- 2718
- Herb2 Meta Analysis Id
- HBMA002718
- Crd Id
- CRD42020168194
- Title
- Effects of Huperzine A on Dementia and Mild Cognitive Impairment: an Overview of Systematic Reviews
- Review Question
- What is the efficacy and effectiveness of Huperzine A in the treatment of dementia and mild cognitive impairment?
- Study Type Included
- All systematic reviews and/or meta-analysis generated from clinical trials that have assessed the efficacy of Huperzine A on Dementia (Alzheimer’s disease or Vascular dementia) or mild cognitive impairment will be included. Systematic reviews that have examined the effect of all types of herbal medicine on dementia and have not specifically examined the effect of Huperzine A will be excluded. We will only include reviews published in the English language.
- Condition Being Studied
- Dementia (Alzheimer’s disease or Vascular dementia) or Mild Cognitive Impairment
- Participant
- Adults, 18 years or older with dementia (Alzheimer’s disease or Vascular dementia or both) of any severity or patients diagnosed with mild cognitive impairment will be included.
- Animal
- Human Disease Modelled
- Intervention
- We will include all reviews in which Huperzine A was taken as an intervention, either alone or with combination of other drugs regardless of manufactures, preparation form, length of treatment, and dosage of Huperzine A which have been used for treatment.
- Comparator Control
- Placebo, no treatment, routine treatment or other pharmacological interventions.
- Main Outcome
- Main outcomes for overview of reviews: Cognitive performance Activity of daily living (ADLs) Global clinical assessment (Global function) Quality of life Safety (Adverse effects) Measures of effect Mwasures of effect will be mean difference or standardized mean difference, or weighted mean difference, or least square mean difference for continuous data, and the relative risk (RR) or odds ratio (OR) for any dichotomous outcome.
- Outcome Measure
- Additional Outcome
- All outcomes are considered core to this overview. Measures of effect Measures of effect will be mean difference or standardized mean difference, or weighted mean difference, or least square mean difference for continuous data, and the relative risk (RR) or odds ratio (OR) for any dichotomous outcome.
- Study Method
- Review of reviews, Systematic review
- Keyword
- Alkaloids; Cognitive Dysfunction; Dementia; Humans; Sesquiterpenes; huperzine A
- Contact
- Mojgan Mirghafourvand [email protected]
- Organisational Affiliation
- Tabriz University of Medical Sciences
- Funding Source
- Tabriz University of Medical Sciences
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Iran
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-02-21
- Registration Date
- 2020-04-28
- Anticipated Start Date
- 2020-02-01
- Anticipated Completion Date
- 2020-09-01
- Title Cn
- 石杉碱甲对痴呆和轻度认知障碍的效果：系统评价的概述
- Title En
- Effects of Huperzine A on Dementia and Mild Cognitive Impairment: an Overview of Systematic Reviews
- Bilingual Status
- complete